Sam Brusco, Associate Editor07.28.22
Zimmer Biomet and Hospital for Special Surgery (HSS) have begun a first-of-its-kind, three-year agreement to create the HSS/Zimmer Biomet Innovation Center for Artifical Intelligence (AI) in Joint Replacement.
The collaboration aims to develop new support decision tools powered by data collection and machine learning for data-driven recommendations that can be given to surgeons for robotic-assisted joint surgery.
"Forging a multi-year collaboration with a leading orthopedics institution combines HSS' clinical expertise with Zimmer Biomet's expertise in surgical robotics and AI modeling," Ivan Tornos, COO at Zimmer Biomet told the press. "This agreement, which is our second collaboration with HSS in two years, advances our vision to accelerate impactful innovation through strategic third-party relationships."
The decision support tools will be integrated into Zimmer Biomet’s ROSA Knee and Hip systems and boost the capabilities of the company’s ZB Edge suite of smart, digital, and robotic technologies that deliver data-powered clinical insights to improve outcomes.
"As a world leader in orthopedics, we strive to find opportunities to innovate towards improving patient care," said Michael P. Ast, MD, chief medical innovation officer at HSS. "Leveraging data analytics and AI in this collaboration could enable us to improve clinical results in robotic-assisted joint replacement surgeries."
A team of HSS surgeons and Zimmer Biomet data scientists will collaborate to develop and test hypotheses that leverage data-driven insights to tackle common joint replacement surgery clinical challenges. The aim is to use the validated hypotheses to inform algorithm development for the decision support tools.
"Through this unique collaboration, HSS can apply our knowledge and expertise to transform musculoskeletal care with innovative technologies that can improve clinical outcomes, patient experience and cost efficiency in a meaningful way," said Louis A. Shapiro, president and CEO at HSS.
"Together we hope to create clinically validated decision support tools that rely on real-world patient and procedural data to inform actionable recommendations that help surgeons achieve predictable and reproducible clinical outcomes," said Nitin Goyal, MD, chief science, technology and innovation officer at Zimmer Biomet.
The collaboration aims to develop new support decision tools powered by data collection and machine learning for data-driven recommendations that can be given to surgeons for robotic-assisted joint surgery.
"Forging a multi-year collaboration with a leading orthopedics institution combines HSS' clinical expertise with Zimmer Biomet's expertise in surgical robotics and AI modeling," Ivan Tornos, COO at Zimmer Biomet told the press. "This agreement, which is our second collaboration with HSS in two years, advances our vision to accelerate impactful innovation through strategic third-party relationships."
The decision support tools will be integrated into Zimmer Biomet’s ROSA Knee and Hip systems and boost the capabilities of the company’s ZB Edge suite of smart, digital, and robotic technologies that deliver data-powered clinical insights to improve outcomes.
"As a world leader in orthopedics, we strive to find opportunities to innovate towards improving patient care," said Michael P. Ast, MD, chief medical innovation officer at HSS. "Leveraging data analytics and AI in this collaboration could enable us to improve clinical results in robotic-assisted joint replacement surgeries."
A team of HSS surgeons and Zimmer Biomet data scientists will collaborate to develop and test hypotheses that leverage data-driven insights to tackle common joint replacement surgery clinical challenges. The aim is to use the validated hypotheses to inform algorithm development for the decision support tools.
"Through this unique collaboration, HSS can apply our knowledge and expertise to transform musculoskeletal care with innovative technologies that can improve clinical outcomes, patient experience and cost efficiency in a meaningful way," said Louis A. Shapiro, president and CEO at HSS.
"Together we hope to create clinically validated decision support tools that rely on real-world patient and procedural data to inform actionable recommendations that help surgeons achieve predictable and reproducible clinical outcomes," said Nitin Goyal, MD, chief science, technology and innovation officer at Zimmer Biomet.
